Novo Nordisk (NVO)

[winston]

not vested

How I knew when to start backing Novo Nordisk’s biggest rival instead

The Danish firm’s complacency is its undoing in the weight-loss drug war

Novo Nordisk has gone from being Europe’s most valuable listed company to losing more than US$300 billion in market value.

by Joyce Hooi

Source: Business Times

https://www.businesstimes.com.sg/opinio ... al-instead

[behappyalways]

Trump's Lilly And Novo Deal Slashes Monthly Weight-Loss Drug Costs By Up To 90%
https://www.zerohedge.com/markets/trump ... loss-drugs

[behappyalways]

Novo Undercuts Lilly's Obesity Drug Price, Now Cheaper Than Car Payment
https://www.zerohedge.com/markets/novo- ... ar-payment

[behappyalways]

Novo Nordisk Plunges After Ozempic Pill Fails Alzheimer's Trials - Shares Suffer Worst Year Ever
https://www.zerohedge.com/markets/novo- ... worst-year

[behappyalways]

"Much-Needed Win": Novo Shares Jump Most In Nearly Two Years After US Approval Of Wegovy Obesity Pill
https://www.zerohedge.com/markets/much- ... vy-obesity

[winston]

not vested

Obesity stocks slump on Novo's underwhelming 2026 sales forecast

Expects sales to drop between 5% and 13% ‍this year, compared with analysts' average expectation of a 2% decline.

Reported a 14% fall in ‌fourth-quarter operating profit to 31.7 billion Danish crowns.

Source: Reuters

https://sg.finance.yahoo.com/news/obesi ... 28439.html

[winston]

not vested

As Novo Nordisk Stock Breaks Below Key Support Levels, Should You Buy the Dip?

by Wajeeh Khan

Oral Wegovy was widely expected to be the ultimate catalyst for NVO stock, but management’s forecast of cooling growth suggests volume gains just can’t outrun eroding prices.

18x forward earnings.

Novo Nordisk shares also remain unattractive to own in 2026 because the selloff on Feb. 3 pushed them decisively below their key moving averages (50-day, 100-day, 200-day).

Moreover, NVO is bracing for the first wave of generic competition as its blockbuster semaglutide loses exclusivity in major international markets like China, Brazil, and Canada.

These fundamental and technical headwinds have options traders pricing in a continued decline in this pharma stock to about $43 by mid-April.

Source: Bar Chart

https://finance.yahoo.com/news/novo-nor ... 38353.html

[behappyalways]

"Big Miss": Wall Street Disappointed After Dismal Novo Nordisk GLP-1 Sales Outlook, Shares Plunge
https://www.zerohedge.com/markets/novo- ... ntensifies

[behappyalways]

$49 Wegovy Copycat Pill Sparks Selloff In Novo Shares
https://www.zerohedge.com/markets/49-we ... ovo-shares

[behappyalways]

Novo Nordisk sues Hims & Hers over copycat versions of Wegovy drugs; Hims stock falls 18%
https://www.cnbc.com/2026/02/09/novo-no ... drugs.html